James F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CEO James F. Oliviero III sold 220,230 shares of the business's stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $3.38, for a total transaction of $744,377.40. Following the sale, the chief executive officer now directly owns 3,194,583 shares in the company, valued at $10,797,690.54. This trade represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Checkpoint Therapeutics Stock Performance

Shares of Checkpoint Therapeutics stock traded up $0.38 during trading on Friday, hitting $3.75. 2,234,921 shares of the company's stock were exchanged, compared to its average volume of 675,598. The stock has a market capitalization of $183.12 million, a price-to-earnings ratio of -2.04 and a beta of 1.34. The business has a 50-day simple moving average of $3.57 and a 200-day simple moving average of $2.70. Checkpoint Therapeutics, Inc. has a 52-week low of $1.38 and a 52-week high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.08). On average, equities analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PVG Asset Management Corp boosted its stake in shares of Checkpoint Therapeutics by 9.2% during the 3rd quarter. PVG Asset Management Corp now owns 149,870 shares of the company's stock worth $336,000 after acquiring an additional 12,676 shares in the last quarter. Virtu Financial LLC purchased a new stake in Checkpoint Therapeutics in the 3rd quarter worth $30,000. Geode Capital Management LLC lifted its stake in Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company's stock valued at $958,000 after buying an additional 124,787 shares in the last quarter. State Street Corp lifted its position in shares of Checkpoint Therapeutics by 32.2% in the third quarter. State Street Corp now owns 94,424 shares of the company's stock valued at $212,000 after acquiring an additional 23,000 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in Checkpoint Therapeutics during the 3rd quarter worth $148,000. Hedge funds and other institutional investors own 22.00% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on the company. Lake Street Capital lifted their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a "buy" rating in a research report on Monday. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Checkpoint Therapeutics in a research note on Monday.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.